Cargando…

Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment

BACKGROUND: Circulating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free survival, breast cancer–specific survival, and overall survival before the start of systemic treatment. METHODS: A total of 200 patients’ sera were included in this study, 100 patients bein...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilsmaier, Theresa, Rack, Brigitte, Janni, Wolfgang, Jeschke, Udo, Weissenbacher, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964055/
https://www.ncbi.nlm.nih.gov/pubmed/27464822
http://dx.doi.org/10.1186/s12885-016-2612-7
_version_ 1782445036248498176
author Vilsmaier, Theresa
Rack, Brigitte
Janni, Wolfgang
Jeschke, Udo
Weissenbacher, Tobias
author_facet Vilsmaier, Theresa
Rack, Brigitte
Janni, Wolfgang
Jeschke, Udo
Weissenbacher, Tobias
author_sort Vilsmaier, Theresa
collection PubMed
description BACKGROUND: Circulating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free survival, breast cancer–specific survival, and overall survival before the start of systemic treatment. METHODS: A total of 200 patients’ sera were included in this study, 100 patients being CTC positive and 100 patients being CTC negative. Matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification and survived breast cancer patients vs. deceased tumor associated patients. A multi cytokine/chemokine array was used to screen the sera for the angiogenic markers. RESULTS: Statistical significant correlation was exposed for sFlt1 values in regard to the CTC-Status. CTC negative patients displayed increased sFlt1 expression opposed to CTC positive breast cancer patients. Furthermore, significant enhanced PIGF values were also disclosed in CTC negative patients compared to patients being CTC positive. Analyzing the living patient collective we found significant differences in sFlt1 and PlGF values in regard to CTC negative and CTC positive patients. CONCLUSION: Both vascular markers showed enhanced expression in the CTC negative patient collective. To continue, the collective graded G2 showed significantly enhanced sFlt1 expressions amongst patients with no CTCs. Moreover, the patient collective with no lymph node metastasis and CTC negativity indicated statistically significant increased sFlt1 values. A functional interaction of sFlt1 and PlGF was found, suggesting that their overexpression in tumour cells inhibits CTCs entering the peripheral blood. Furthermore, in regard to CTC negativity, sFlt1 and PlGF values may potentially serve as predictive markers. TRIAL REGISTRATION: The TRN of this study is NCT02181101 and the date of registration was the 4(th) of June 2014. The study was retrospectively registered.
format Online
Article
Text
id pubmed-4964055
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49640552016-07-29 Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment Vilsmaier, Theresa Rack, Brigitte Janni, Wolfgang Jeschke, Udo Weissenbacher, Tobias BMC Cancer Research Article BACKGROUND: Circulating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free survival, breast cancer–specific survival, and overall survival before the start of systemic treatment. METHODS: A total of 200 patients’ sera were included in this study, 100 patients being CTC positive and 100 patients being CTC negative. Matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification and survived breast cancer patients vs. deceased tumor associated patients. A multi cytokine/chemokine array was used to screen the sera for the angiogenic markers. RESULTS: Statistical significant correlation was exposed for sFlt1 values in regard to the CTC-Status. CTC negative patients displayed increased sFlt1 expression opposed to CTC positive breast cancer patients. Furthermore, significant enhanced PIGF values were also disclosed in CTC negative patients compared to patients being CTC positive. Analyzing the living patient collective we found significant differences in sFlt1 and PlGF values in regard to CTC negative and CTC positive patients. CONCLUSION: Both vascular markers showed enhanced expression in the CTC negative patient collective. To continue, the collective graded G2 showed significantly enhanced sFlt1 expressions amongst patients with no CTCs. Moreover, the patient collective with no lymph node metastasis and CTC negativity indicated statistically significant increased sFlt1 values. A functional interaction of sFlt1 and PlGF was found, suggesting that their overexpression in tumour cells inhibits CTCs entering the peripheral blood. Furthermore, in regard to CTC negativity, sFlt1 and PlGF values may potentially serve as predictive markers. TRIAL REGISTRATION: The TRN of this study is NCT02181101 and the date of registration was the 4(th) of June 2014. The study was retrospectively registered. BioMed Central 2016-07-27 /pmc/articles/PMC4964055/ /pubmed/27464822 http://dx.doi.org/10.1186/s12885-016-2612-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Vilsmaier, Theresa
Rack, Brigitte
Janni, Wolfgang
Jeschke, Udo
Weissenbacher, Tobias
Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
title Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
title_full Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
title_fullStr Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
title_full_unstemmed Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
title_short Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
title_sort angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964055/
https://www.ncbi.nlm.nih.gov/pubmed/27464822
http://dx.doi.org/10.1186/s12885-016-2612-7
work_keys_str_mv AT vilsmaiertheresa angiogeniccytokinesandtheirinfluenceoncirculatingtumourcellsinseraofpatientswiththeprimarydiagnosisofbreastcancerbeforetreatment
AT rackbrigitte angiogeniccytokinesandtheirinfluenceoncirculatingtumourcellsinseraofpatientswiththeprimarydiagnosisofbreastcancerbeforetreatment
AT janniwolfgang angiogeniccytokinesandtheirinfluenceoncirculatingtumourcellsinseraofpatientswiththeprimarydiagnosisofbreastcancerbeforetreatment
AT jeschkeudo angiogeniccytokinesandtheirinfluenceoncirculatingtumourcellsinseraofpatientswiththeprimarydiagnosisofbreastcancerbeforetreatment
AT weissenbachertobias angiogeniccytokinesandtheirinfluenceoncirculatingtumourcellsinseraofpatientswiththeprimarydiagnosisofbreastcancerbeforetreatment
AT angiogeniccytokinesandtheirinfluenceoncirculatingtumourcellsinseraofpatientswiththeprimarydiagnosisofbreastcancerbeforetreatment